Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying ixabepilone to see how well it works compared to
mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not
responded to paclitaxel, docetaxel, or hormone therapy. Drugs used in chemotherapy work in
different ways to stop tumor cells from dividing so they stop growing or die. Some tumors
become resistant to chemotherapy drugs. Ixabepilone may reduce resistance to the drugs and
allow the tumor cells to be killed. It is not yet known which chemotherapy regimen is more
effective in treating metastatic prostate cancer